Sofosbuvir in therapy of chronic HCV-infection

Objective of review: to present new approaches to therapy of patients with chronic NCV-infection based on the clinical use of the direct antiviral action drug Sofosbuvir.

Major provisions: until recently a standard approach to therapy of HCV-infection included prescription of schemes on the basis of the pegylated interferons (PEG-IFN) in combination with Ribavirin. Drugs of focused action at functional proteins of the virus – direct anti￾viral drugs – have become drugs of choice, which significantly increases effectiveness and safety of treatment. Drugs of direct antiviral action are classified by the type of viral proteins that serve as the target of their action: protease inhibitors (names of the drugs end with - previr), polymerase inhibitors (names of the drugs end with –buvir), NS5A inhibitors (names of the drugs end with – asvir).

Sofosbuvir is an analogue of the uridine nucleotide, a powerful NS5B inhibitor, a key enzyme of HCV-RNA replication, it is widely used in various scheme of antiviral therapy.

Conclusion: Sofosbuvir is one of the most promising drugs for therapy of chronic NCV-infection. Its indisputable advantages: it can be used at various viral genotypes, decompensated liver function. Sofosbuvir stands out for its good tolerability and low possibility of development of viral resistance. 

1. Tan SL, ed. Hepatitis C Viruses: Genomes and Molecular Biology. Norfolk (UK): Horizon Bioscience, 2006.

2. Kowdley KV, Lawitz E, Crespo I, Hassanein T, Davis MN, DeMicco M, et al. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatmentnaive patients with hepatitis C genotype-1 infection (ATOMIC): An open-label, randomised, multicentre phase 2 trial. Lancet, 2013, 381: 2100-7.

3. Jacobson IM, Gordon SC, Kowdley KV, Yoshida EM, Rodriguez-Torres M, Sulkowski MS et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med, 2013, 368: 1867-77.

4. Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med, 2013, 368: 1878-87.

5. Zeng QL, Zhang JY, Zhang Z, Wang LF, Wang FS. Sofosbuvir and ABT-450: Terminator of hepatitis C virus? World J Gastroenterol, 2013, 19: 3199-206.

6. Herbst DA Jr, Reddy KR. Sofosbuvir, a nucleotide polymerase inhibitor, for the treatment of chronic hepatitis C virus infection. Expert Opin Investig Drugs, 2013, 22: 527-36.

7. Soriano V, Vispo E, de Mendoza C, Labarga P, Fernandez-Montero JV, Poveda E, et al. Hepatitis C therapy with HCV NS5B polymerase inhibitors. Expert Opin Pharmacother, 2013, 14: 1161-70.

8. Gentile I, Borgia F, Buonomo AR, Castaldo G, Borgia G. A novel promising therapeutic option against hepatitis C virus: An oral nucleotide NS5B polymerase inhibitor sofosbuvir. Curr Med Chem, 2013, 20: 3733-42.

9. Tseng A. Drug Interactions with Investigational Hepatitis C Nucleotide Inhibitors; Sofosbuvir. Ин тер нет-страница: http://www.hcvdruginfo.ca/ down loads/Hepatitis%20C-int_new%20nucleotide%20inhibitors.pdf. [Последний доступ 08.2016 г.].

10. An Open-Label Study of Sofosbuvir/Ledipasvir Fixed-Dose Combination in subjects with nosocomial genotype 1 HCV infection. Интернет- страница: http:// clinicaltrials.gov/ct2/show/ NCT01924949 [Последний доступ 08.2016 г.].

11. Open-Labeled Study of PSI-7977 and RBV with and without PEG-IFN in Treatment-naïve Patients with HCV GT2 or GT3. Интернет- страница: http:// clinicaltrials. gov/show/ NCT01260350 [Последний доступ 08.2016 г.].

12. Sofosbuvir Containing Regimens for the Treatment of Chronic HCV Infection in Subjects with Chronic Genotype 1, 2, or 3 HCV Infection. Интернет- страница: http://clinicaltrials.gov/ct2/show/ NCT01826981 [Последний доступ 08.2016 г.].

13. Safety and Efficacy of Sofosbuvir/GS-5885 Fixed-dose Combination ± Ribavirin for the Treatment of HCV (ION-2). Интернет-страница: http:// clinicaltrials.gov/show/NCT01768286 [Последний доступ 08.2016 г.].

14. EASL Recommendations on Treatment of Hepatitis C 2015. Интернет-страница http:// www.easl.eu/medias/cpg/HEPC-2015/Full￾report.pdf [Последний просмотр 08.2016 г.].

15. Bhatia HK, Singh H, Grewal N, Natt NK. Sofosbuvir: A novel treatment option for chronic hepatitis C infection. J Pharmacol Pharmacother, 2014 Oct, 5(4): 278-84.

16. Highlyman L. Polymerase Inhibitor PSI-7977 Works with Interferon or Companion Drug. Coverage of the 46th Annual Meeting of the European Association for the Study of the Liver. 2011 April. Интернет-страница: http:// www. hivandhepatitis.com/2011_ conference/ easl2011/docs/0404_2010_ d.html [Последний доступ 08.2016 г.].

17. An Open-Label Study of Sofosbuvir/Ledipasvir Fixed-Dose Combination in subjects with nosocomial genotype 1 HCV infection. Интернет- страница: http:// clinicaltrials.gov/ct2/show/ NCT01924949 [Последний доступ 08.2016 г.].

18. Open-Labeled Study of PSI-7977 and RBV with and without PEG-IFN in Treatment-naïve Patients with HCV GT2 or GT3. Интернет- страница: http:// clinicaltrials. gov/show/ NCT01260350 [Последний доступ 08.2016 г.].

19. Safety and Efficacy of Sofosbuvir/GS-5885 Fixed-dose Combination ± Ribavirin for the Treatment of HCV (ION-2). Интернет-страница: http:// clinicaltrials.gov/show/NCT01768286 [Последний доступ 08.2016 г.

20. Data from Phase 3 Studies of Gilead’s Sofosbuvir for Hepatitis C to be Presented at 48thAnnual EASL Meeting; Findings Published Online in The New England Journal of Medicine. 2013 April. Интернет-страница: http:// www.gilead.com/news/press-releases/2013/4/datafrom-phase-3-studies-ofgileads-sofosbuvir-for-hepatitis-c [Последний доступ 08.2016 г.].

21. Soriano V, Vispo E, de Mendoza C, Labarga P, Fernandez-Montero JV, Poveda E, et al. Hepatitis C therapy with HCV NS5B polymerase inhibitors. Expert Opin Pharmacother, 2013, 14: 1161-70.

22. Lam AM, Espiritu C, Bansal S, MicolochickSteuer HM, Niu C, Zennou V, et al. Genotype and sub￾type pro-ling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus. Antimicrob Agents Chemother, 2012, 56: 3359-68.

23. Rodriguez-Torres M, Lawitz E, Kowdley KV, Nelson DR, Dejesus E, McHutchison JG, et al. Sofosbuvir (GS- 7977) plus peginterferon/ribavirin in treatmentnaïve patients with HCV genotype 1: A randomized, 28-day, dose-ranging trial. J Hepatol, 2013, 58: 663-8.

24. Levin J. GS-7977 and HIV ARTs PK – No Clinically Significant Pharmacokinetic Interactions between Sofosbuvir (GS-7977) and HIV Antiretro virals Atripla, Rilpivirine, Darunavir/Ritonavir, or Raltegravir in Healthy Volunteers. AASLD 63rd Annual Meeting of the American Association for the Study of Liver Diseases. 2012 Nov. Интернет- страница: http://www.natap.org/2012/AASLD/ AASLD_64.htm. [Последний доступ 08.2016 г.].